Skip to search.
 All Ordinaries Up0.78%

More On NRT.AX

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials


Novogen Ltd (NRT.AX)

-ASX
0.20 0.00(0.00%) 30 Jul 16:11
Add to Portfolio
ProfileGet Profile for:
Novogen Ltd
16 - 20 Edgeworth David Avenue
Suite 1
Hornsby, NSW 2077
Australia - Map
Phone: 61 2 9472 4100
Fax: 61 2 9476 0388
Website: http://www.novogen.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:N/A

Business Summary 

Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which include super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which include Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, including glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer. The company’s ATMs technology platform targets the cytoskeleton of the cancer cell. Novogen Limited was founded in 1994 and is based in Hornsby, Australia.

Key Statistics


Company Websites 
Home Page
Search Yahoo!7 for:
More on Novogen Ltd

Key Executives 
 PayExercised
Mr. Iain Gladstone Ross B.SC (HONS), C.DIR , 61
Acting Chief Exec. Officer and Director
18.00kN/A
Christine Bruce ,
Acting Chief Financial Officer and Financial Controller
37.00kN/A
Dr. David Brown B.App. Sc. (Hons), Ph.D., GradDip,
Chief Scientific Officer
N/AN/A
Mr. Lionel Mateo BCL MCL,
Company Sec.
N/AN/A
Dr. Andrew Heaton B.Sc (Hons) Ph.D.,
Vice-Pres of Drug Discovery, Manufacture & Patents
N/AN/A
Amounts are as of 31/12/2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in AUD.
View Insiders